These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
466 related articles for article (PubMed ID: 28243692)
41. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity. McAndrews KM; Che SPY; LeBleu VS; Kalluri R J Biol Chem; 2021; 296():100523. PubMed ID: 33711340 [TBL] [Abstract][Full Text] [Related]
42. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T Benoit-Lizon I; Jacquin E; Rivera Vargas T; Richard C; Roussey A; Dal Zuffo L; Martin T; Melis A; Vinokurova D; Shahoei SH; Baeza Garcia A; Pignol C; Giorgiutti S; Carapito R; Boidot R; Végran F; Flavell RA; Ryffel B; Nelson ER; Soulas-Sprauel P; Lawrence T; Apetoh L J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091453 [TBL] [Abstract][Full Text] [Related]
43. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467 [TBL] [Abstract][Full Text] [Related]
44. Activation of STING signaling accelerates skin wound healing. Mizutani Y; Kanbe A; Ito H; Seishima M J Dermatol Sci; 2020 Jan; 97(1):21-29. PubMed ID: 31813660 [TBL] [Abstract][Full Text] [Related]
45. Assessing the cGAS-cGAMP-STING Activity of Cancer Cells. Pépin G; Gantier MP Methods Mol Biol; 2018; 1725():257-266. PubMed ID: 29322423 [TBL] [Abstract][Full Text] [Related]
46. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Li S; Luo M; Wang Z; Feng Q; Wilhelm J; Wang X; Li W; Wang J; Cholka A; Fu YX; Sumer BD; Yu H; Gao J Nat Biomed Eng; 2021 May; 5(5):455-466. PubMed ID: 33558734 [TBL] [Abstract][Full Text] [Related]
47. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. Ni H; Zhang H; Li L; Huang H; Guo H; Zhang L; Li C; Xu JX; Nie CP; Li K; Zhang X; Xia X; Li J J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36126994 [TBL] [Abstract][Full Text] [Related]
48. Pharmacological Activation of cGAS for Cancer Immunotherapy. Garland KM; Rosch JC; Carson CS; Wang-Bishop L; Hanna A; Sevimli S; Van Kaer C; Balko JM; Ascano M; Wilson JT Front Immunol; 2021; 12():753472. PubMed ID: 34899704 [TBL] [Abstract][Full Text] [Related]
49. Cyclic dinucleotides modulate induced type I IFN responses in innate immune cells by degradation of STING. Rueckert C; Rand U; Roy U; Kasmapour B; Strowig T; Guzmán CA FASEB J; 2017 Jul; 31(7):3107-3115. PubMed ID: 28396343 [TBL] [Abstract][Full Text] [Related]
50. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622 [TBL] [Abstract][Full Text] [Related]
51. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy. Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039 [TBL] [Abstract][Full Text] [Related]
52. Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer. Yu J; Deng H; Xu Z Sci Rep; 2020 Dec; 10(1):21360. PubMed ID: 33288772 [TBL] [Abstract][Full Text] [Related]
53. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553 [TBL] [Abstract][Full Text] [Related]
54. Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. Lee E; Jang HE; Kang YY; Kim J; Ahn JH; Mok H Acta Biomater; 2016 Jan; 29():271-281. PubMed ID: 26485167 [TBL] [Abstract][Full Text] [Related]
55. He Y; Hong C; Irvine DJ; Li J; Hammond PT Bio Protoc; 2021 Feb; 11(3):e3905. PubMed ID: 33732792 [TBL] [Abstract][Full Text] [Related]
56. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8 Yin W; Song Y; Liu Q; Wu Y; He R Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970 [TBL] [Abstract][Full Text] [Related]
57. Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells. Watkins-Schulz R; Batty CJ; Stiepel RT; Schmidt ME; Sandor AM; Chou WC; Ainslie KM; Bachelder EM; Ting JP Mol Pharm; 2022 Sep; 19(9):3125-3138. PubMed ID: 35913984 [TBL] [Abstract][Full Text] [Related]
58. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474 [TBL] [Abstract][Full Text] [Related]
59. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271 [TBL] [Abstract][Full Text] [Related]
60. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]